These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9396709)

  • 1. Regulatory considerations for Campylobacter vaccine development.
    Kopecko DJ
    J Infect Dis; 1997 Dec; 176 Suppl 2():S189-91. PubMed ID: 9396709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines against Campylobacter jejuni.
    Scott DA
    J Infect Dis; 1997 Dec; 176 Suppl 2():S183-8. PubMed ID: 9396708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Status of vaccine research and development for Campylobacter jejuni.
    Riddle MS; Guerry P
    Vaccine; 2016 Jun; 34(26):2903-2906. PubMed ID: 26973064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A capsule conjugate vaccine approach to prevent diarrheal disease caused by Campylobacter jejuni.
    Maue AC; Poly F; Guerry P
    Hum Vaccin Immunother; 2014; 10(6):1499-504. PubMed ID: 24632556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Campylobacter jejuni infection and Guillain-Barre syndrome.
    Aguago JM; Ramos JT; Lumbreras C
    N Engl J Med; 1996 Mar; 334(12):802. PubMed ID: 8592566
    [No Abstract]   [Full Text] [Related]  

  • 6. Update on Campylobacter jejuni vaccine development for preventing human campylobacteriosis.
    Jagusztyn-Krynicka EK; Łaniewski P; Wyszyńska A
    Expert Rev Vaccines; 2009 May; 8(5):625-45. PubMed ID: 19397419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guillain-Barre syndrome and Campylobacter jejuni infection. A study on the etiological characteristics of Guillain-Barre syndrome in China.
    Yuan JM; Tang J; Chen QT; Xiao L; Hao HJ; Jia ZD; Huang QH; Liu XZ
    Chin Med J (Engl); 1993 Nov; 106(11):845-7. PubMed ID: 8143497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advances in the research on the pathogenic role of Campylobacter jejuni in Guillain-Barre syndrome].
    Tang J; Yuan JM
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1992 Dec; 25(6):375-7. PubMed ID: 1305004
    [No Abstract]   [Full Text] [Related]  

  • 9. GM1 antibody in Guillain-Barre syndrome after Campylobacter jejuni infection.
    Tang J; Yuan J; Hao H
    Chin Med J (Engl); 1995 Apr; 108(4):262-4. PubMed ID: 7789212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbiologic approaches for studying Campylobacter species in patients with Guillain-Barré syndrome.
    Nachamkin I
    J Infect Dis; 1997 Dec; 176 Suppl 2():S106-14. PubMed ID: 9396692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Campylobacter jejuni strain CG8421: a refined model for the study of Campylobacteriosis and evaluation of Campylobacter vaccines in human subjects.
    Tribble DR; Baqar S; Carmolli MP; Porter C; Pierce KK; Sadigh K; Guerry P; Larsson CJ; Rockabrand D; Ventone CH; Poly F; Lyon CE; Dakdouk S; Fingar A; Gilliland T; Daunais P; Jones E; Rymarchyk S; Huston C; Darsley M; Kirkpatrick BD
    Clin Infect Dis; 2009 Nov; 49(10):1512-9. PubMed ID: 19842970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between Campylobacter infection and Guillain-Barré syndrome.
    Allos BM
    J Infect Dis; 1997 Dec; 176 Suppl 2():S125-8. PubMed ID: 9396695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Campylobacter jejuni bacteremia and Guillain-Barré syndrome in a patient with GVHD after allogeneic BMT.
    Hagensee ME; Benyunes M; Miller JA; Spach DH
    Bone Marrow Transplant; 1994 Mar; 13(3):349-51. PubMed ID: 8199580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies.
    Ho TW; Mishu B; Li CY; Gao CY; Cornblath DR; Griffin JW; Asbury AK; Blaser MJ; McKhann GM
    Brain; 1995 Jun; 118 ( Pt 3)():597-605. PubMed ID: 7600081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and data analysis of experimental trials to test vaccine candidates against zoonotic pathogens in animals: the case of a clinical trial against campylobacter in broilers.
    Garcia AB; Bahrndorff S; Hald B; Hoorfar J; Madsen M; Vigre H
    Expert Rev Vaccines; 2012 Oct; 11(10):1179-88. PubMed ID: 23176651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiologic and clinical features of Campylobacter jejuni infections.
    Blaser MJ
    J Infect Dis; 1997 Dec; 176 Suppl 2():S103-5. PubMed ID: 9396691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Campylobacter jejuni enteritis and Guillain-Barré syndrome].
    Yuki N
    Rinsho Byori; 1999 Aug; 47(8):713-8. PubMed ID: 10511801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders.
    Enders U; Karch H; Toyka KV; Michels M; Zielasek J; Pette M; Heesemann J; Hartung HP
    Ann Neurol; 1993 Aug; 34(2):136-44. PubMed ID: 8338338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain-Barré syndrome and Miller Fisher syndrome.
    Yuki N
    J Infect Dis; 1997 Dec; 176 Suppl 2():S150-3. PubMed ID: 9396700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on Campylobacter vaccine development.
    Poly F; Noll AJ; Riddle MS; Porter CK
    Hum Vaccin Immunother; 2019; 15(6):1389-1400. PubMed ID: 30252591
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.